Date of Award
Master of Science (MS)
Dr. Jeremy Mercuri, Committee Chair
Dr. William King
Dr. Martine LaBerge
Dr. Jennifer Woodell-May
Osteoarthritis (OA) is a debilitating and painful disease that affects upwards of one in every eight adults1,2. OA influences the entire joint, but is traditionally characterized by cartilage degradation3. OA is a multifactorial disease with genetic, biological, and biochemical consideration, but there has been a recent shift in scientific opinion that the pathological progression of OA stems from an inflammatory milieu produced by the feed-forward progressive pathway as evidenced by simultaneous cartilage and synovium co-culture4–7. Autologous protein solution (APS) poses as an intriguing potential OA therapy by possessing a high anti-inflammatory and anabolic mediator concentration profile that could potentially mitigate the progression of OA8.
A human OA in vitro co-culture model with patient-matched cartilage and synovium was validated and used to analyze the effects of APS on OA progression. The outcome measures used to assess OA co-culture with and without APS included: cell viability, histological, and biochemical assays including enzyme-linked immunosorbent assays (ELISA) and dimethyl methylene blue (DMMB) assays. The co-culture model exhibited the hallmarks of OA including pathologically progressive cartilage destruction and the presence of inflammatory cytokines.
APS treatment showed encouraging results in mitigating OA as APS treated co-culture cartilage experienced less chondrocyte cloning and a general increase of anti-inflammatory mediators within the OA environment. Given these results, APS could be a promising OA mitigation therapy to evaluate further in in vivo trials.
1. Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014;10(7):437-441. doi:10.1038/nrrheum.2014.44.
2. Musumeci G, Aiello F, Szychlinska M, Di Rosa M, Castrogiovanni P, Mobasheri A. Osteoarthritis in the XXIst Century: Risk Factors and Behaviours that Influence Disease Onset and Progression. Int J Mol Sci. 2015;16(3):6093-6112. doi:10.3390/ijms16036093.
3. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697-1707. doi:10.1002/art.34453.
4. Sutton S, Clutterbuck A, Harris P, et al. The contribution of the synovium, synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis. Vet J. 2009;179(1):10-24. doi:10.1016/j.tvjl.2007.08.013.
5. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet. 2005;365(9463):965-973. doi:10.1016/S0140-6736(05)71086-2.
6. Topoluk N, Steckbeck K, Siatkowski S, Burnikel B, Tokish J, Mercuri J. Validation of an In Vitro Co-Culture Model Comprised of Human Osteoarthritic Joint Tissue Explants. In: Orthopaedic Research Society. Orlando, FL, USA; 2016.
7. Beekhuizen M, Bastiaansen-jenniskens YM, Koevoet W, et al. Osteoarthritic synovial tissue inhibition of proteoglycan production in human osteoarthritic knee cartilage: establishment and characterization of a long-term cartilage-synovium coculture. Arthritis Rheum. 2011;63(7):1918-1927. doi:10.1002/art.30364.
8. Woodell-May J, Matuska A, Oyster M, Welch Z, O’Shaughnessey K, Hoeppner J. Autologous protein solution inhibits MMP-13 production by IL-1β and TNFα-stimulated human articular chondrocytes. J Orthop Res. 2011;29(9):1320-1326. doi:10.1002/jor.21384.
Steckbeck, Kathleen Emily, "Autologous Protein Solution Exhibits Potential to Mitigate Osteoarthritis (OA) Progression in a Human Explant Co-Culture Model" (2016). All Theses. 3031.